Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2021 09:01 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Scientific Data; Company Reports Third Quarter Financial Results

Data continue to support mavorixafor’s potential to benefit patients with WHIM syndrome, chronic neutropenia, and Waldenström’s macroglobulinemia Discovery of new prevalent WHIM variant further...
November 01, 2021 16:05 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
October 25, 2021 08:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021

BOSTON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
October 19, 2021 08:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Directors and Karolyn Park as Vice President, U.S. Commercial

BOSTON, Oct. 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients...
October 04, 2021 08:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome

Final enrollment of 31 adult and pediatric patients exceeds initial target of 18-28 patients Top-line data expected in 4Q 2022; U.S. NDA filing anticipated in 1Q 2023 BOSTON, Oct. 04, 2021 (GLOBE...
October 01, 2021 16:05 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
September 15, 2021 16:05 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting...
September 08, 2021 08:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Promotes Mary DiBiase, Ph.D. to Chief Operating Officer

BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting...
September 01, 2021 16:01 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the...
September 01, 2021 08:00 ET | Source: X4 Pharmaceuticals

X4 Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting...